Navigation Links
Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors

NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that Alan J. Lacy has been elected to its Board of Directors, effective January 2, 2008. Lacy will serve as a member of the Audit Committee.

Lacy, 54, is currently a senior advisor to Oak Hill Capital Partners, L.P., a private equity investment firm. From 1994 to 2006, he was employed by Sears, Roebuck and Co. and following the acquisition of the company, Sears Holdings Corporation. He held executive level positions of increasing responsibility in finance and operations, including his service as chief executive officer from 2000 to 2005. He also served as vice chairman from 2005 to 2006.

"We are very pleased to have a person of Alan's broad business and financial experience join our Board," said James D. Robinson III, chairman, Bristol-Myers Squibb. "His addition adds to an already outstanding group of directors."

"Alan is a man of high integrity and business acumen," added James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "We look forward to his contributions as a director of our company as we continue to evolve into a next generation biopharma enterprise."

Bristol-Myers Squibb is a global biopharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Bristol-Myers Squibb Announces Dividend
2. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
3. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
4. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
5. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
6. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
7. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Mediware Names Thomas K. Mann Chief Executive Officer
10. Cleveland-based Health Care Tech Company Within3 Names New CEO
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: